|
AU698393B2
(en)
|
1994-06-24 |
1998-10-29 |
Immunex Corporation |
Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
|
|
IL112834A
(en)
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
|
US6020004A
(en)
|
1997-04-17 |
2000-02-01 |
Amgen Inc. |
Biodegradable microparticles for the sustained delivery of therapeutic drugs
|
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
US6432449B1
(en)
|
1998-05-18 |
2002-08-13 |
Amgen Inc. |
Biodegradable sustained-release alginate gels
|
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
|
NZ526720A
(en)
*
|
2000-12-28 |
2007-11-30 |
Altus Pharmaceuticals Inc |
Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
|
|
US8821086B2
(en)
*
|
2006-12-22 |
2014-09-02 |
Tennine Corporation |
Method and apparatus for controlled-fracture machining
|
|
WO2008109871A2
(en)
*
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
CN101679527A
(zh)
*
|
2007-04-13 |
2010-03-24 |
诺瓦提斯公司 |
用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US9994923B2
(en)
*
|
2008-04-23 |
2018-06-12 |
Amgen Inc. |
Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
|
|
KR100985090B1
(ko)
*
|
2008-05-23 |
2010-10-04 |
한국과학기술연구원 |
크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
|
|
WO2011028938A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
WO2011053783A2
(en)
*
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax213 and ax132 pcsk9 antagonists and variants
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
PL3395836T3
(pl)
*
|
2011-01-28 |
2021-12-13 |
Sanofi Biotechnology |
Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
US20140004122A1
(en)
*
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
ITPN20110039A1
(it)
*
|
2011-05-24 |
2012-11-25 |
Keyline S P A |
Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP2849788B1
(en)
*
|
2012-05-17 |
2018-01-03 |
Cyon Therapeutics Inc. |
Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
|
|
EP2861624A1
(en)
*
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
WO2014145744A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Alder Biopharmaceuticals, Inc. |
Antibody purification and purity monitoring
|
|
JP2016514668A
(ja)
*
|
2013-03-15 |
2016-05-23 |
アムジエン・インコーポレーテツド |
プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質
|
|
TW202021614A
(zh)
*
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
US20150004174A1
(en)
*
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
JP6267792B2
(ja)
*
|
2013-06-28 |
2018-01-24 |
アムジエン・インコーポレーテツド |
ホモ接合性家族性高コレステロール血症の治療方法
|
|
KR20220048051A
(ko)
*
|
2013-10-11 |
2022-04-19 |
사노피 바이오테크놀로지 |
고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
|
|
MX2016006226A
(es)
*
|
2013-11-12 |
2016-09-07 |
Sanofi Biotechnology |
Regimenes de dosificacion para uso con inhibidores de pcsk9.
|
|
US8883157B1
(en)
*
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
*
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
*
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
CN106029096A
(zh)
*
|
2014-02-14 |
2016-10-12 |
瑞泽恩制药公司 |
用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
|
|
EP3107937A4
(en)
*
|
2014-02-21 |
2017-11-15 |
MedImmune, LLC |
Anti-pcsk9~glp-1 fusions and methods for use
|
|
WO2015140079A1
(en)
*
|
2014-03-17 |
2015-09-24 |
Sanofi |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
AU2015231713B2
(en)
*
|
2014-03-17 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing cardiovascular risk
|
|
AU2015289874A1
(en)
*
|
2014-07-14 |
2017-02-02 |
Amgen Inc. |
Crystalline antibody formulations
|
|
WO2016010924A1
(en)
*
|
2014-07-14 |
2016-01-21 |
Amgen Inc. |
Crystalline antibody formulations
|
|
PL3169353T3
(pl)
*
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
|
EP3197492A1
(en)
*
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
WO2017177094A2
(en)
*
|
2016-04-08 |
2017-10-12 |
Amgen Inc. |
Drug delivery device, method of manufacture, and method of use
|
|
WO2017186928A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
SG10201912565QA
(en)
*
|
2016-09-29 |
2020-02-27 |
Amgen Inc |
Low-viscosity antigen binding proteins and methods of making them
|
|
EP3522918A1
(en)
*
|
2016-10-06 |
2019-08-14 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
JOP20190112A1
(ar)
*
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
US20190031774A1
(en)
*
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
BR112020007405A2
(pt)
*
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
|
JP7332691B2
(ja)
*
|
2018-07-08 |
2023-08-23 |
スペシフィカ インコーポレイティド |
抗体の開発可能性が最大化された抗体ライブラリー
|